Contact
Please use this form to send email to PR contact of this press release:
Molecular Templates, Inc. Announces Dosing of First Subject in Phase I Study of TAK-169 in Relapsed/Refractory Multiple Myeloma
TO:
Please use this form to send email to PR contact of this press release:
Molecular Templates, Inc. Announces Dosing of First Subject in Phase I Study of TAK-169 in Relapsed/Refractory Multiple Myeloma
TO: